Business
PharmaCielo Signs Sales Agreement and Makes Initial Commercial Sale to Pharmaceutical Player in Brazil
PharmaCielo Signs Sales Agreement and Makes Initial Commercial Sale to Pharmaceutical Pla...
About this update from Pharmacielo Ltd.
[{"type":"text","content":"\n \n \n \n PharmaCielo Signs Sales Agreement and Makes Initial Commercial Sale to Pharmaceutical Player in Brazil\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n \n The Customer is focused on medicine development, manufacture and distribution, and is one of the first pharmaceutical players to be fully licensed by the Brazilian Health Regulatory Agency (ANVISA) to produce cannabis products in the country.\n \n \n \n \n Agreement covers two CBD-dominant formulations and two THC-dominant formulations.\n \n \n \n \n Represents continued traction in the Brazilian market following the Company's\n \n April 26\n \n \n th\n \n announcement that it had made\n \n initial shipments to one of\n \n Brazil's\n \n largest Phyto-Therapeutics companies as well as to a large Pharmaceutical company in the market\n \n .\n \n \n \n \n \n TORONTO\n \n and RIONEGRO,\n \n Colombia\n \n ,\n \n Aug. 4, 2021\n \n /CNW/ - PharmaCielo Ltd. (\"PharmaCielo\" or the \"Company\") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of\n \n Colombia's\n \n premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that it has signed a sales agreement (the \"Agreement\") with a cannabis-focused pharmaceutical player in the Brazilian market (the \"Customer\"), following an on-site visit by the Customer during\n \n July 2021\n \n . The Customer is present in many countries in\n \n South America\n \n ,\n \n Europe\n \n and\n \n Asia\n \n , and is in the process of registering and seeking to distribute its cannabis products in these markets in the near-term.\n \n \n \n \n \n \n \n \n \n The Agreement covers a selection of PharmaCielo products, including CBD Isolate, CBD Full Spectrum, THC Full Spectrum and THC Distillate. In conjunction with the Agreement, PharmaCielo made an initial commercial sale of CBD Isolate to the Customer. The Company expects to begin shipping additional CBD and THC formulations during Q4 2021 once final product registrations and import permits, are in place in\n \n Brazil\n \n .\...